100041-3 |
Aminoglycoside |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Aminoglycoside [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100041-3 |
|
|
|
|
Both |
|
|
|
0 |
Aminoglycoside Susc Islt |
|
|
|
N |
|
Amikacin; Aminoglycosides; ANTIBIOTIC SUSCEPTIBILITIES; AST; c288; Gentamicin; Islt; Isol; Neomycin; Point in time; Random; Streptomycin; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Tobramycin |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100042-1 |
Atovaquone |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Atovaquone [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100042-1 |
|
|
|
|
Both |
|
|
|
0 |
Atovaquone Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Atavaquone; Islt; Isol; Mepron; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100043-9 |
Azithromycin+Ethambutol |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Azithromycin+Ethambutol [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100043-9 |
|
|
|
|
Both |
|
|
|
0 |
Azithro+Ethambut Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Azithro+Ethambut; Etambol; Ethamb; Inagen; Islt; Isol; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Zithromax |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100044-7 |
Cefcapene |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Cefcapene [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100044-7 |
|
|
|
|
Both |
|
|
|
0 |
Cefcapene Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100045-4 |
Cefozopran |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Cefozopran [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100045-4 |
|
|
|
|
Both |
|
|
|
0 |
Cefozopran Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100046-2 |
Cefquinome |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Cefquinome [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100046-2 |
|
|
|
|
Both |
|
|
|
0 |
CEQ Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; CEQ; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100047-0 |
Cefteram |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Cefteram [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100047-0 |
|
|
|
|
Both |
|
|
|
0 |
Cefteram Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefterame; Cefteramum; Ceftetrame; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100048-8 |
Clarithromycin+Ethambutol |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Clarithromycin+Ethambutol [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100048-8 |
|
|
|
|
Both |
|
|
|
0 |
Clarithro+Ethamb Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Biaxin; Claripen; Clarithro+Ethamb; Etambol; Ethamb; Inagen; Islt; Isol; Klacid; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100049-6 |
Eravacycline |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Eravacycline [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100049-6 |
|
|
|
|
Both |
|
|
|
0 |
Eravacycline Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
10005-7 |
R wave duration.lead V2 |
Time |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
R wave duration in lead V2 |
|
MIN |
DefinitionDescription |
|
|
s |
|
|
|
|
|
|
EKG.MEAS |
|
10005-7 |
|
EKG |
|
|
Observation |
|
|
|
0 |
R wave dur L-V2 |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; Durat; ECG; EKG.MEASUREMENTS; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; R prime; R' wave dur L-V2; R wave dur L-V2; Random; Right |
2.48 |
1.0i |
|
|
|
|
|
|
|
s |
|
|
|
0 |
|
100050-4 |
Erythromycin+Ethambutol |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Erythromycin+Ethambutol [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100050-4 |
|
|
|
|
Both |
|
|
|
0 |
Erythro+Ethamb Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; c212; EES; Erygel; Erythro+Ethamb; Erythromycn; Etambol; Ethamb; Ilosone; Ilotycin; Iltycin; Inagen; Islt; Isol; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100051-2 |
Ethambutol+rifAMPin |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Ethambutol+rifAMPin [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100051-2 |
|
|
|
|
Both |
|
|
|
0 |
Ethambutol+rifAMPin Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; c301; Etambol; Ethamb; Inagen; Islt; Isol; Myambutol; Mycobutol; Olbutam; Point in time; Random; RIF; Rifadin; Rifampicin; Rimactane; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100052-0 |
Flomoxef |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Flomoxef [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100052-0 |
|
|
|
|
Both |
|
|
|
0 |
Flomoxef Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Flomoxefum; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100053-8 |
Fluoroquinolone |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Fluoroquinolone [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100053-8 |
|
|
|
|
Both |
|
|
|
0 |
FLQ Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; FLQ; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100054-6 |
Gamithromycin |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Gamithromycin [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100054-6 |
|
|
|
|
Both |
|
|
|
0 |
Gamithromycin Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Bovine Respiratory Disease; BRD; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Vet; Veterinary; Zactran |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100055-3 |
Optochin |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Optochin [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100055-3 |
|
|
|
|
Both |
|
|
|
0 |
Optochin Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100056-1 |
Panipenem |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Panipenem [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100056-1 |
|
|
|
|
Both |
|
|
|
0 |
Panipenem Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Panipenum; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100057-9 |
Prothionamide |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Prothionamide [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100057-9 |
|
|
|
|
Both |
|
|
|
0 |
Prothionamide Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Protionamide; PTH; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100058-7 |
Prulifloxacin |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Prulifloxacin [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100058-7 |
|
|
|
|
Both |
|
|
|
0 |
Prulifloxacin Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Pruquin; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100059-5 |
Rifapentine |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Rifapentine [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100059-5 |
|
|
|
|
Both |
|
|
|
0 |
Rifapentine Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
10006-5 |
R wave duration.lead V3 |
Time |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
R wave duration in lead V3 |
|
MIN |
DefinitionDescription |
|
|
s |
|
|
|
|
|
|
EKG.MEAS |
|
10006-5 |
|
EKG |
|
|
Observation |
|
|
|
0 |
R wave dur L-V3 |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; Durat; ECG; EKG.MEASUREMENTS; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; R prime; R' wave dur L-V3; R wave dur L-V3; Random; Right |
2.48 |
1.0i |
|
|
|
|
|
|
|
s |
|
|
|
0 |
|
100060-3 |
Tildipirosin |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Tildipirosin [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100060-3 |
|
|
|
|
Both |
|
|
|
0 |
Tildipirosin Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Bovine Respiratory Disease; BRD; Islt; Isol; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Vet; Veterinary; Zuprevo |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100061-1 |
Tosufloxacin |
Susc |
Isolate |
Pt |
OrdQn |
|
|
ACTIVE |
Tosufloxacin [Susceptibility] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
100061-1 |
|
|
|
|
Both |
|
|
|
0 |
Tosufloxacin Susc Islt |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Islt; Isol; Ozex; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|
100062-9 |
Standard Dermatology Outcome Measures panel |
- |
^Patient |
Pt |
- |
SDOM |
|
ACTIVE |
Standard Dermatology Outcome Measures panel |
|
ADD |
DefinitionDescription |
|
|
|
|
Copyright �© 2016 The Regents of the University of California and Emory University. Used with permission. |
|
|
|
|
PANEL.CLIN |
|
100062-9 |
|
SDOM |
|
|
Order |
|
|
|
0 |
SDOM panel |
|
|
|
N |
|
CLIN; Pan; PANEL.CLINICAL; Panl; Pnl; Point in time; Random; SDOM panel |
2.72 |
2.72 |
|
Panel |
|
|
Copyright �© 2016 The Regents of the University of California and Emory University. Used with permission. |
|
|
|
|
|
|
0 |
|
100063-7 |
Primary skin concern |
Find |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Primary skin concern |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CLIN |
|
100063-7 |
|
|
|
|
Observation |
|
|
|
0 |
Primary skin concern |
|
|
|
N |
|
CLIN; Finding; Findings; Integument; Nominal; Point in time; Random |
2.72 |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
0 |
|